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Abstract 
Previously, we identified a metabotropic glutamate receptor 4 (mGluR4) as a potential target for drugs and predicted that 
activation of mGluR4 could provide a palliative advantage in the treatment of Parkinson's disease. Determine the mechanism 
of action of Rapitalam in vitro on a cell culture with mGluR4 over expression. The HEK293T cell line expressing human 
mGluR4 was used in the work. Receptor activity was assessed by the level of calcium in the cytoplasm, the release of which is 
stimulated by the addition of glutamate. It is seen that Rapitalam significantly increases the cellular response induced by an 
agonist. On cell culture with superexpression of mGluR4 we have shown that Rapitalm is a positive allosteric modulator of 
mglur4 receptor. 
 
Introduction 
 
 Parkinson's disease is a slow-progressive chronic 
neurodegenerative disease that affects about 1% of 
people over 55 years of age. At the heart of Parkinson's 
disease is the progressive destruction and death of 
neurons that produce the neurotransmitter dopamine, 
primarily in a black substance [1, 2]. The leading 
symptoms of Parkinson's disease are: muscle rigidity, 
hypokinesia, tremor, postural instability [3]. 
Dopamine-replacement therapy provides a significant 
improvement in the motor symptoms of Parkinson's 
disease in the early stages of the disease. However, 
long-term treatment with these drugs leads to loss of 
efficacy and the appearance of motor and cognitive 
side effects [4]. In addition, there is an assumption that 
l-dopa therapy can accelerate the progression of the 
disease by increasing oxidative damage [2, 4]. 
Therefore, the interest of scientists is directed to the 
development of therapeutic methods of treatment that 
can bypass the dopamine system. These methods were 
based on the findings obtained from the results of 
surgical interventions in the treatment of Parkinson's 
disease. So pallidotomy or deep stimulation of the 
brain showed a significant effect in patients with severe 
manifestations of Parkinson's disease [5, 6]. These 
methods led to a refinement of the model of basal 
ganglia dysfunction associated with Parkinson's disease 
[7]. Basal ganglia are a set of interconnected nuclei that 
play a key role in the management of movements. The 
main input nucleus of the basal ganglia is the striatum, 
which is innervated by the cortex and subcortical 
structures, such as the thalamus. Corticostrial and 
thalamocortical pathways are excitatory glutamatergic 
pathways. 
Brain gamma-amino-butyric acid (GABA) is used 
in the striatopallidarnom and pallidotalamicheskim 
ways [2, 8]. Thus, this model assumes that there are 
two ways between the striatum and the output nuclei of 
the basal ganglia. In Parkinson's disease, the loss of 
dopaminergic tone of the striatum leads to increased 
activation of the indirect pathway and a decrease in 
activity in the direct way, which ultimately leads to an 
increase and inadequate inhibition of thalamocortical 
neurons [8]. Surgical interventions circumvent the 
dopamine system and lead to a reduction in 
dysfunction in the indirect pathway. Therefore, a 
pharmacological intervention that mimics these 
surgical techniques can provide palliative care to a 
larger number of patients without the need for invasive 
surgery. In addition, treatment by bypassing the 
dopamine system should result in fewer side effects 
and can actually slow the disease process by 
normalizing the overactive glutamatergic entry into the 
dopamine-containing neurons of the midbrain [8, 9]. 
Previously, we identified a metabotropic glutamate 
receptor 4 (mGluR4) as a potential target for drugs and 
predicted that activation of mGluR4 could provide a 
palliative advantage in the treatment of Parkinson's 
disease [10, 11]. 
 
Objectives of the Study 
 
Determine the mechanism of action of Rapitalam in 
vitro on a cell culture with mGluR4 over expression. 
 
Materials and Methods 
 
Cell line: The HEK293T cell line expressing human 
mGluR4 was used in the work. 
Maintenance of the cell line: 
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Medium: DMEM (Hyclone, USA) with 5% FBS 
(Hyclone, USA), 1% essential amino acids, 2mM L-
Glutamine, 1mM sodium pyruvate, 1% penicillin / 
streptomycin (Invitrogen), 0.4 mg / ml G418 (Sigma, 
USA ). 
Cells are grown in culture flasks of 175 cm2 to 90% 
confluency. After the culture medium is removed by a 
vacuum pump, the cell layer is gently moistened with 
0.53 mM EDTA solution to remove traces of the 
medium and incubated 5-10 minutes before the cells 
are removed from the substrate. 8 ml of culture 
medium is added to prepare the cell suspension by neat 
mixing. The cell suspension is centrifuged for 2 
minutes at 120 g. The EDTA-containing medium is 
removed and replaced with 10 ml of fresh medium. 
The cells are placed in vials with a dilution of the 
original culture 4-10 times. 
The cell concentration is calculated by a 
hemocytometer and the required volume of the cell 
suspension is adjusted with a culture medium without 
FBS to a concentration of 1000 cells / μl (giving a cell 
density of 25,000 cells per well) with the addition of 
aprotinin to a concentration of 10.5 mg / l. The cell 
suspension is transferred to 25 μl each well of the 
required number of culture plates with a poly-D-lysine 
coating using a Biomek NXp384 workstation. The 
plates are centrifuged at 50g for 30 "and transferred to 
a CO2 incubator (37 ° C in a humidified atmosphere 
with 5% CO2) for 12-16 hours. 
On the day of the experiment, cells are "loaded" 
with Ca2 + -sensitive paint in accordance with the 
protocol of the kit manufacturer. Briefly, 20 ml of 
Essenia Buffer (HBSS) is added to dissolve the 
lyophilized Ca2 + -sensitive paint in the vial and the 
resulting solution is used as a 25X drain as 
recommended by the manufacturer. A 1x paint working 
solution is prepared by diluting a 25x stock solution in 
an Essenia buffer containing 0.2% pluronic acid F-127 
and 5mM probenicide.The prepared 1x working 
solution is poured into the reservoir and transferred 
with a Biomek NXp384 workstation to 25 μl per each 
well of the culture plate with the cells placed in it on 
the previous day. Further, the plates with cells are 
transferred to storage in a CO2 incubator (37 ° C in a 
humidified atmosphere with 5% CO2) for 2 hours, after 
which the plates must be used directly for carrying out 
the essay on the FLIPR. 
Preparation of dies with a solution of test 
compounds in DMSO: 
The ratals were dissolved in DMSO to give a 30 
mM solution. Further serial dilutions were made in 
384-well plates with a dilution step of 3.16, 10 
concentration points and two repetitions at each 
concentration point, respectively, in the following 
scheme (see Figure 1): 
 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
A                         
В                         
C                         
D                         
E                         
F                         
G                         
H                         
I                         
J                         
K                         
L                         
M                         
N                         
O                         
P                         
 
Columns 3-22 in rows C-N: serial dilutions of the compounds from 30 mM, 40 μl per well 
Columns 2.23 and rows B, O - 40 μl DMSO (used for controls) 
    Columns 1.24 and rows A, P are not used in view of the presence of an edge effect. 
 Figure 1. Diagram of a die with compounds dissolved in DMSO 
 
Preparation of intermediate dissolution plates: 
Using the Biomek FXp384 workstation, transfer 
199 μl of Essenia buffer containing 0.1% pluronic acid 
F-127 to the required number of Axygen Scientific dies 
(VWR, Cat. No. 47743-466) from the reservoir. Using 
a Biomek FXp384 workstation, 1 μl from each well of 
the plate with substances dissolved in DMSO at a 
concentration of 30 mM is transferred to the 
corresponding wells of the plate containing 199 μl of 
Essenia buffer and mixed 6 times to obtain a 5x 
working solution of the substances. The control wells 
are filled according to the scheme (see Fig. 2): 
 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
A                         
D                         
C                         
D                         
E                         
F                         
G                         
H                         
I                         
D
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J                         
K                         
L                         
M                         
N                         
O                         
P                         
Glutamat 
 
 
substance from 
150 мкМ 
 
Figure 2. Diagram of the intermediate dissolution plate of the compounds. 
 
Preparation of a plate with agonist: 
Glutamate is dissolved in Essenia buffer containing 
0.1% Pluronic acid F-127 to produce a 6x working 
solution (E 
 
C20) and transferred from the reservoir using the 
Biomek FXp384 workstation to the Axygen Scientific 
plate. The scheme of filling holes in a plate with an 
agonist is given below (see Fig. 3): 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
A                         
D   + + + + + + + + + + + + + + + + + + + +   
C                       _  
D                       _  
E                       _  
F                       _  
G                       _  
H                       _  
I                       _  
J                       _  
K                       _  
L                       _  
M                       _  
N                       _  
O   + + + + + + + + + + + + + + + + + + + +   
P                         
Glutamat 
buffer 
+ control 
– control 
Figure 3. Diagram of a plate with an agonist. Reading plates on FLIPRtetra 
 
For 12.5 μl of a 5 × solution from each well of a 
plate with intermediate dissolution of the substances is 
transferred by the FLIRPtetra device (Molecular 
Devices, CA) to the corresponding wells of the plate 
with the cells preloaded with Ca2 + -sensitive paint as 
described above and read for 0.1 sec every 1 second for 
5 minutes and once every 6 seconds for 10 minutes to 
determine whether there is agonism or the cytotoxic 
effect of the analytes (total incubation time with the 
substances before adding the agonist 15 minutes). 
Further, 12.5 μl of 6 × Glutamate solution is transferred 
to the plate and the signal is read out for 0.1 second 
every 1 second for 5 minutes. 
Parameters of control wells: Positive control of 
agonistic activity (EC100 Glutamate = 100% mGluR4 
activation) - wells B2-O2. Negative control of agonist 
activity (0% mGluR4 activation - buffer): wells B23-
O23. Total reaction volume: 75 μl. The final 
concentration of DMSO: 0.01% 
 
Results 
 
Receptor activity was evaluated on the culture of 
cells superexpressing the human mGluR4 receptor, 
according to the level of calcium in the cytoplasm, the 
release of which is stimulated by the addition of an 
agonist (glutamate). It can be seen that in itself, the 
Ratalam does not activate the release of calcium 
(Figure 4, black triangles). In this case, Rapitalam 
significantly increases the cellular response (Figure 4, 
blue) induced by the agonist (glutamate, Figure 4, red). 
Thus, the obtained data prove the mechanism of the 
action of Rapitalam as a positive allosteric modulator 
of human mGluR4 receptor. 
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Figure 4. Rapitalam enhances the activity of glutamate. The experiment was performed on HEK293T - mGluR4 
cells. Red cells in the presence of glutamate, black cells in the presence of Rapitalam, blue cells in the presence of 
Rapitalam and glutamate. 
 
Conclusion 
 
Studies of specific antiparkinsonian activity and the 
mechanism of action of the pharmaceutical substance, 
in vivo, have been carried out. On cell culture with 
mGluR4 overexpression, we have been shown that 
Rapitalam is a positive allosteric modulator of the 
mGluR4 receptor. The Rapitalam have a concentration-
dependent increase in the cellular response induced by 
glutamate. 
The search for new safe compounds that affect 
synaptic transmission is an important task of modern 
pharmacology [12]. In addition, the choice of adequate 
in vitro models can optimize and accelerate preclinical 
studies [13]. 
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